EpimAb Biotherapeutics Announces Oral Presentation for EMB-06 (CND106) First-in-human (FIH) Phase I Study in Multiple Myeloma at the American Society of Hematology (ASH) 2024 Annual Meeting
05. Dezember 2024 20:00 ET
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce the...